Eneficial effects in different illness models. Having said that, most mammalian cells secret modest level of EV, which is a limitation for development of therapeutics. For that reason, the subsequent generation of EV-mimetic vesicles produced by serial extrusion of cells produces greater number of vesicles, and could be simpler to scale up for therapeutic developments. In this study we aimed to test the efficacy of EV-mimetic vesicles derived from human adipose-derived stem cells (hASCs) on rat osteoarthritis (OA) model. Procedures: hASC-derived EV-mimetic vesicles (CDV) had been made by serial extrusions of cells via filters. The CDVs have been characterized by transmission electron microscopy (TEM), nanoparticle evaluation system (NTA), and western blot and flow cytometry. CDVs had been injected into the joints in a MIA-induced osteoarthritis (OA) rat model. Improvement of pain following CDV injections was assessed by paw withdrawal threshold and weight bearing, whereas the joint destruction was evaluated by histology. We also estimated the effects of CDV on proliferation and migration of human chondrocytes in vitro by cell-counting and Prolactin Proteins MedChemExpress scratch assays. Outcomes: The CDV had been 5050 nm in diameter and carried multiple EV-associated tetraspanins (CD63, CD9, CD81). CDV-treated OA mice had reduced paw withdrawal and was much more weight bearing 17 days right after therapy than PBS-treated. Additional, histology showed reduced joint defects at 24 days. CDV-treated OA models displayed considerable improvement in pawJOURNAL OF EXTRACELLULAR VESICLESwithdrawal behaviour and weight bearing evaluation. Similarly, chondrocyte migration and proliferation were enhanced by CDV in a dose-dependent manner. Summary/Conclusion: This study demonstrates for the first time the efficacy of hASC EV-mimetic vesicles in OA model. Most interestingly we’ve confirmed that hASC EV-mimetic vesicles can increase discomfort and regenerate defected cartilage. These benefits help the idea that a possible application of hASC EVmimetic is osteoarthritis, by providing CDV locally into affected joints.Funding: This project is sponsored by NIH grant R01DE027404 as well as the Osteology Foundation Advanced Researcher award.PF08.Exosomes secreted for the duration of chondrogenic differentiation of human adipose-derived stem cells for osteoarthritis remedy Ye eun Yuna, Woo Sung Kima, Hyun-A Parkb, Su Yeon Kimb and Yong Woo Choc Division of Chemical Engineering, Hanyang University, Ansan, Republic of Korea; bExostemtech,Inc., Ansan, Republic of Korea; cHanyang University, Ansan, Republic of KoreaaPF08.Organic and synthetic biomaterial mediated delivery of Mesenchymal Stem Cell derived exosomes Chun-Chieh Huanga, Miya Kanazawab, Praveen Gajendrareddyc and Sriram Ravindranaa University of Illinois at Chicago, Chicago, IL, USA; bUIC College of Dentistry, Oral Biology, Chicago, IL, USA; cUniversity of Illinois, Chicago, Chicago, IL, USAIntroduction: Mesenchymal stem cell (MSC) derived exosomes are versatile agents that possess immunomodulatory and regenerative properties. However, systemic delivery of all-natural or engineered MSC exosomes lacks site-specificity and can trigger ectopic effects. Therefore, biomaterial-mediated site-specific delivery of exosomes is vital. As exosomal membranes are subsets with the plasma membrane. We hypothesized that MSC exosomes can bound to extracellular CD28 Proteins Storage & Stability matrix proteins and the home is often made use of as a delivery technique. Approaches: To test this hypothesis, we evaluated the binding and delivery kinetics of MSC exosomes to a.